Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study - Mukenge, Eric Kasongo; Sumbu, Blaise Matondo-Manzambi; Nkodila, Aliocha Natuhoyila; Muwonga, Jeremie Masidi; Makulo, Jean-Robert Rissassi; Ngole, Mamy Zita; Bepouka, Ben Izizag; Longokolo, Murielle Mashi; Kamwiziku, Guyguy; Situakibanza, Hippolyte Nanituma; Kayembe, Jean-Marie Ntumba; Longo-Mbenza, Benjamin; et al. (BMC infectious diseases, 2025)
Keywords: Adult; Aged; Analysis; Antibodies; Antibodies, Viral - blood; Anticoagulants; Clinical trials; Comorbidity; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Creatinine; Democratic Republic of Congo; Democratic Republic of the Congo - epidemiology; Drug dosages; Female; Hazard identification; Health aspects; Hematology; Humans; IgG; Immune system; Immunity; Immunization; Immunoglobulin G; Immunoglobulins; Incidence; Male; Medical research; Medicine, Experimental; Middle Aged; mRNA; Physiological aspects; Prospective Studies; Public health; RNA; SARS-CoV-2 - immunology; Seroconversion; Serology; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Viral antibodies; Democratic Republic of the Congo; Congo (Kinshasa); United Kingdom; United Kingdom--UK; IgG; COVID-19 vaccine; Seroconversion; Democratic Republic of Congo